Danielle Brill
Stock Analyst at Truist Securities
(3.92)
# 567
Out of 5,173 analysts
104
Total ratings
45.16%
Success rate
12.28%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Initiates: Hold | $83 | $79.24 | +4.75% | 1 | Mar 18, 2026 | |
| CLYM Climb Bio | Initiates: Buy | $17 | $6.54 | +159.94% | 1 | Mar 18, 2026 | |
| MAZE Maze Therapeutics | Initiates: Buy | $68 | $49.00 | +38.78% | 1 | Mar 18, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $63 → $110 | $79.32 | +38.68% | 3 | Mar 9, 2026 | |
| IRON Disc Medicine | Maintains: Buy | $114 → $83 | $59.11 | +40.42% | 8 | Feb 27, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $86 → $95 | $69.60 | +36.49% | 4 | Feb 25, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $169 → $140 | $127.05 | +10.19% | 9 | Feb 17, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $38 | $26.00 | +46.15% | 3 | Jan 29, 2026 | |
| TECX Tectonic Therapeutic | Maintains: Buy | $64 → $60 | $29.44 | +103.80% | 3 | Jan 8, 2026 | |
| IMVT Immunovant | Maintains: Hold | $16 → $22 | $24.38 | -9.76% | 6 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $45 | $27.60 | +63.04% | 9 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $535 → $530 | $306.66 | +72.83% | 3 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105 → $190 | $117.04 | +62.34% | 4 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $8.45 | +456.21% | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $451.24 | - | 3 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $19.46 | +23.33% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $20 → $52 | $15.92 | +226.63% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $21.09 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $54.78 | +44.21% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $8.34 | +115.83% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $17.71 | +746.98% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $183.64 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $681.85 | -11.27% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $20.99 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $54.42 | -8.12% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $28.11 | +81.43% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $7.03 | +1,323.49% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $66.42 | - | 9 | Sep 18, 2023 |
Apogee Therapeutics
Mar 18, 2026
Initiates: Hold
Price Target: $83
Current: $79.24
Upside: +4.75%
Climb Bio
Mar 18, 2026
Initiates: Buy
Price Target: $17
Current: $6.54
Upside: +159.94%
Maze Therapeutics
Mar 18, 2026
Initiates: Buy
Price Target: $68
Current: $49.00
Upside: +38.78%
Dianthus Therapeutics
Mar 9, 2026
Maintains: Buy
Price Target: $63 → $110
Current: $79.32
Upside: +38.68%
Disc Medicine
Feb 27, 2026
Maintains: Buy
Price Target: $114 → $83
Current: $59.11
Upside: +40.42%
BridgeBio Pharma
Feb 25, 2026
Maintains: Buy
Price Target: $86 → $95
Current: $69.60
Upside: +36.49%
Neurocrine Biosciences
Feb 17, 2026
Maintains: Buy
Price Target: $169 → $140
Current: $127.05
Upside: +10.19%
Centessa Pharmaceuticals
Jan 29, 2026
Maintains: Buy
Price Target: $33 → $38
Current: $26.00
Upside: +46.15%
Tectonic Therapeutic
Jan 8, 2026
Maintains: Buy
Price Target: $64 → $60
Current: $29.44
Upside: +103.80%
Immunovant
Jan 8, 2026
Maintains: Hold
Price Target: $16 → $22
Current: $24.38
Upside: -9.76%
Jan 8, 2026
Maintains: Buy
Price Target: $48 → $45
Current: $27.60
Upside: +63.04%
Jan 8, 2026
Maintains: Buy
Price Target: $535 → $530
Current: $306.66
Upside: +72.83%
Dec 16, 2025
Maintains: Buy
Price Target: $105 → $190
Current: $117.04
Upside: +62.34%
Oct 14, 2025
Initiates: Buy
Price Target: $47
Current: $8.45
Upside: +456.21%
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $451.24
Upside: -
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $19.46
Upside: +23.33%
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $15.92
Upside: +226.63%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $21.09
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $54.78
Upside: +44.21%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $8.34
Upside: +115.83%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $17.71
Upside: +746.98%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $183.64
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $681.85
Upside: -11.27%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $20.99
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $54.42
Upside: -8.12%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $28.11
Upside: +81.43%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $7.03
Upside: +1,323.49%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $66.42
Upside: -